|
|
Article: Seattle Genetics Expands Research Programs Through Exclusive License from Imperial College London.
- Article from:
- Business Wire
- Article date:
- May 19, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors & Health/Medical Writers
BOTHELL, Wash.--(BUSINESS WIRE)--May 19, 2004
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has entered into a license agreement with Imperial College Innovations Limited, the technology transfer company of Imperial College London, for exclusive rights to a novel monoclonal antibody targeting a cell surface tumor-associated antigen. Seattle Genetics plans to evaluate the therapeutic potential of the antibody against a variety of cancers, including hematologic malignancies and solid tumors such as breast, colon and bladder cancer.
"This agreement provides us with a valuable addition to our ...